Gdynia, Poland Clinical Trials

A listing of Gdynia, Poland clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 100 clinical trials
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3

This study is designed to evaluate the long-term efficacy and safety of mirikizumab in participants with moderately to severely active ulcerative colitis (UC).

mirikizumab
Endoskopia Sp. z.o.o.
 (5.6 away) Contact site
  • 326 views
  • 20 Oct, 2022
  • +317 other locations
A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)

This is a randomized, active-controlled, open-label study of pembrolizumab (Pembro) given prior to surgery and pembrolizumab in combination with standard of care radiotherapy (with or without cisplatin), as post-surgical therapy in treatment naïve participants with newly diagnosed Stage III/IVA, resectable, locoregionally advanced, head and neck squamous cell carcinoma (LA-HNSCC). Efficacy …

squamous cell carcinoma
metastasis
squamous cell carcinoma of head and neck
dental caries
intensity-modulated radiation therapy
Szpitale Pomorskie Sp. z o.o. ( Site 0935)
 (3.0 away) Contact site
  • 96 views
  • 20 Oct, 2022
  • +129 other locations
A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322) (BRUIN CLL-322)

The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm B) in patients with CLL/SLL who have been previously treated with at least one prior line of therapy. Participation could last up to five …

chronic lymphocytic leukemia
rituximab
lymphoma
venetoclax
neutrophil count
Szpitale Pomorskie Sp. z o. o.
 (2.4 away) Contact site
  • 0 views
  • 22 Oct, 2022
  • +128 other locations
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody) in Patients With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (SKYSCRAPER-07)

The purpose of this study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo in participants with unresectable esophageal squamous cell carcinoma (or those who are unable or unwilling to undergo surgery) and whose cancers have not progressed following definitive concurrent chemoradiotherapy (dCRT). Participants will …

squamous cell carcinoma
chemoradiotherapy
esophagus cancer
esophageal cancer
concurrent chemoradiation
Szpital Morski im. PCK; Poradnia Onkologiczna
 (2.2 away) Contact site
  • 7 views
  • 22 Oct, 2022
  • +165 other locations
A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-3)

The purpose of this study is to compare the efficacy of teclistamab-daratumumab (Tec-Dara) with daratumumab subcutaneously (SC) in combination with pomalidomide and dexamethasone (DPd) or daratumumab SC in combination with bortezomib and dexamethasone (DVd) in Part 1 and to evaluate the pharmacokinetics (PK), safety, and efficacy of the Tec-Dara regimen …

progressive disease
lenalidomide
measurable disease
bortezomib
refractory multiple myeloma
Klinika Hematologii i Transplantologii, UCK
 (8.6 away) Contact site
  • 0 views
  • 21 Oct, 2022
  • +156 other locations
A 52-Week, Multicenter, Randomized, Double-blind, Placebo and Active-Controlled, Operationally Seamless Phase 2b/3, Parallel-group Study to Assess the Efficacy and Safety of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease (INTREPID Lead-In) (INTREPID)

This study seeks to evaluate the safety and efficacy of brazikumab versus placebo (Stage I) and versus an active comparator (Stage 2) in participants with moderately to severely active CD and will include assessments of clinical response as demonstrated by improvement of symptoms and colonic mucosal appearance as observed on …

methotrexate
azathioprine
mercaptopurine
budesonide
endoscopy
Research Site
 (5.4 away) Contact site
  • 550 views
  • 20 Oct, 2022
  • +77 other locations
A Phase III, Open-Label, Randomized Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Patients With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer Who Have Not Progressed After Concurrent Platinum-Based Chemoradiation (SKYSCRAPER-03)

The purpose of this study is to evaluate the efficacy and safety of atezolizumab in combination with tiragolumab compared with durvalumab in participants with locally advanced, unresectable Stage III non-small cell lung cancer (NSCLC) who have received at least two cycles of concurrent platinum-based chemoradiotherapy (CRT) and have not had …

chemoradiotherapy
lung carcinoma
atezolizumab
platinum-based chemotherapy
cancer chemotherapy
Uniwersyteckie Centrum Kliniczne; Klinika Onkologii i Radioterapii
 (8.6 away) Contact site
  • 0 views
  • 23 Oct, 2022
  • +169 other locations
Comprehensive Assessment of Erenumab Efficacy in Subjects With High Frequency Episodic Migraine With at Least 1 Previously Failed Preventive Treatment: a Global, Double-blind, Placebo-controlled Phase 4 Study (EMBRACE)

The primary objective of this study is to evaluate the treatment benefit of erenumab on headache duration of at least moderate pain intensity.

erenumab
episodic migraine
acute migraine
triptan
rizatriptan
Centrum Badan Klinicznych PI-House Spzoo
 (9.9 away) Contact site
  • 366 views
  • 23 Oct, 2022
  • +63 other locations
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI)

The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with Crohn's disease.

crohn's disease
abdominal pain
Endoskopia Sp z o.o.
 (5.6 away) Contact site
  • 0 views
  • 23 Oct, 2022
  • +92 other locations
A Phase III, Randomized, Open-Label, Multicenter Study of Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab as Maintenance Therapy in Participants With Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following First-Line Induction Therapy With Carboplatin, Etoposide and Atezolizumab (IMforte)

Study GO43104 is a Phase III, randomized, open-label, multicenter study of lurbinectedin in combination with atezolizumab compared with atezolizumab alone administered as maintenance therapy in participants with extensive-stage small-cell lung cancer (ES-SCLC) after first-line induction therapy with carboplatin, etoposide, and atezolizumab. The study consists of 2 phases: an induction phase …

prophylactic cranial irradiation
lurbinectedin
atezolizumab
etoposide
carboplatin
Uniwersyteckie Centrum Kliniczne; Klinika Onkologii i Radioterapii
 (8.6 away) Contact site
  • 2 views
  • 23 Oct, 2022
  • +77 other locations